Pacific Biosciences (PACB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting opened with a welcome and introduction of board members and key executives in attendance virtually.
Agenda included addressing proposals from the proxy statement and a Q&A session post-adjournment.
Shareholder proposals
Four proposals were presented: election of directors, ratification of the independent auditor, advisory vote on executive compensation, and amendment to the 2020 Equity Incentive Plan.
Board recommended approval of all proposals.
Overview of voting outcomes
All nominated directors were elected for terms expiring in 2027.
Ratification of Ernst & Young LLP as independent auditor was approved.
Advisory approval of executive compensation passed.
Amendment to the 2020 Equity Incentive Plan, increasing reserved shares by 16 million, was approved.
Latest events from Pacific Biosciences
- Strong clinical growth, new product launches, and cost cuts set stage for 2027–2028 profitability.PACB
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue was $39.0M, with lower margins and guidance, and major restructuring actions.PACB
Q2 2026 - SPARQ-Nx and workflow advances fuel clinical growth, margin gains, and global expansion.PACB
TD Cowen 46th Annual Health Care Conference - Record consumable growth, clinical expansion, and cost discipline drive path to profitability.PACB
Goldman Sachs 46th Annual Global Healthcare Conference - Long read sequencing adoption is accelerating due to cost parity, clinical demand, and new data advantages.PACB
Stephens Annual Investment Conference - HiFi sequencing delivers superior accuracy, throughput, and resolution for microbial genomics and metapangenomics.PACB
Status update - Record consumable growth, Basecamp AI deal, and SPRQ-Nx launch drive strong outlook.PACB
Jefferies Global Healthcare Conference 2026 - Record consumables and improved margins offset lower instrument sales, with new technology launched.PACB
Q3 2025 - Q3 revenue up sequentially, new products and debt restructuring set stage for 2025 growth.PACB
Q3 2024 - Record consumables growth and cost cuts offset weak instrument sales and major restructuring losses.PACB
Q1 2025